Mark Mikinski, MD
Interventional Cardiology · Salina, KSNPI 1467418897
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,312 of the $12,835 with a category attached, or 88.1%. 34 manufacturers reported payments, led by Medtronic at 45.6% of the total.
Across 680 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Boston Scientific$2K
- Novartis$853
- Pfizer$611
- Merck$558
- AstraZeneca$502
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1,49212%
- Food & beverage$11,31288%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 269 | $5,857 |
| Boston Scientific | 81 | $1,745 |
| Novartis | 65 | $853 |
| Pfizer | 45 | $611 |
| Merck | 38 | $558 |
| AstraZeneca | 31 | $502 |
| E.r. Squibb & Sons, L.L.C. | 36 | $489 |
| Amgen | 21 | $376 |
| Abiomed | 9 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $244 |
| Johnson & Johnson | 16 | $243 |
| Boehringer Ingelheim | 10 | $160 |
| Regeneron Healthcare Solutions, Inc. | 8 | $134 |
| Amarin Pharma, Inc. | 5 | $98 |
| Cvrx, Inc. | 2 | $75 |
| Stryker | 2 | $72 |
| Gilead | 3 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Shockwave Medical, Inc | 1 | $40 |
| Bardy Diagnostics, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Philips North America LLC | 1 | $31 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Infobionic, Inc | 1 | $17 |
| Novo Nordisk | 1 | $14 |
| Penumbra, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,288
- Micra$498
- COREVALVE EVOLUT R$127
- SYMPLICITY G3$119
How this compares
$12,835 in reported general payments places this provider in the 55th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 168 | $157,424 |
| EliquisApixaban | 147 | $129,011 |
| JardianceEmpagliflozin | 80 | $53,491 |
| XareltoRivaroxaban | 41 | $30,454 |
| FarxigaDapagliflozin Propanediol | 41 | $28,575 |
| Repatha SureclickEvolocumab | 22 | $20,793 |
| Praluent PenAlirocumab | 14 | $12,802 |
| ClopidogrelClopidogrel Bisulfate | 412 | $3,601 |
| Digoxin | 119 | $2,148 |
| Metoprolol Succinate | 174 | $2,145 |
| Amiodarone Hcl | 66 | $1,280 |
| Atorvastatin Calcium | 147 | $847 |
| Rosuvastatin Calcium | 88 | $812 |
| Metoprolol Tartrate | 171 | $798 |
| Carvedilol | 153 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $853 | $157,424168 claims |
| PfizerEliquis | $611 | $129,011147 claims |
| Boehringer IngelheimJardiance | $160 | $53,49180 claims |
| Johnson & JohnsonXarelto | $243 | $30,45441 claims |
| AstraZenecaFarxiga | $502 | $28,57541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Salina
- David BattinSalina$30K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Priyantha RanaweeraManhattan$41K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
- John SerfasKansas City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.